Paper Details

  1. Home
  2. Paper Details

[Desmopressin parenteral in patients with VWD1, VWD 2A and thrombocytopathy].

Author: PollmannH, SiegmundB

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Desmopressin (DDAVP) was effective in treating von Willebrand disease type 1 but also caused side effects.
Paper Details　
Original Abstract of the Article :
Desmopressin (DDAVP, Minirin® parenteral), which induces the release of von-Willebrand factor from endogenous stores, is indicated in von Willebrand disease type 1 (VWD 1). In the present study effectiveness of DDAVP was tested and side effects were recorded in patients with VWD 1, von Willebrand di...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/22057258

データ提供：米国国立医学図書館（NLM）

Desmopressin: A Treatment Option for Von Willebrand Disease and Thrombocytopathy

Von Willebrand disease (VWD) and thrombocytopathy are bleeding disorders that can affect individuals of all ages. This study delves into the world of hemostatic therapy, exploring the use of desmopressin (DDAVP), a synthetic analog of vasopressin, in treating patients with VWD type 1, VWD type 2A, and thrombocytopathy. The researchers investigated the effectiveness of DDAVP in increasing von Willebrand factor levels and improving clotting function in these patients, while also carefully monitoring for any side effects.

Exploring the Therapeutic Potential of Desmopressin

The study evaluated the effectiveness of desmopressin in treating patients with different types of bleeding disorders. The research provides valuable insights into the potential benefits of desmopressin as a treatment option for VWD and thrombocytopathy, offering a potential alternative to other therapies.

Improving Bleeding Disorder Management

This study highlights the potential of desmopressin to improve the management of bleeding disorders. The research underscores the importance of considering desmopressin as a treatment option for patients with VWD and thrombocytopathy, particularly in cases where other therapies may not be suitable.

Dr.Camel's Conclusion

This study sheds light on the therapeutic potential of desmopressin for treating bleeding disorders. It encourages further investigation into the optimal use of desmopressin in managing these conditions, potentially leading to improved patient outcomes and a better understanding of the role of this medication in hemostatic therapy.

Date :
  1. Date Completed 2012-03-30
  2. Date Revised 2014-07-30
Further Info :

Pubmed ID

22057258

DOI: Digital Object Identifier

11410S29

Related Literature

Article Analysis
・Side Effects of desmopressin
SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.